This Opinion article discusses the challenges in determining which genomic events in tumours are actionable and thus expected to affect treatment response. The authors summarize published classification approaches and propose a new framework to classify mutation actionability in early-phase clinical trials.
- T. Hedley Carr
- Robert McEwen
- J. Carl Barrett
